Categories: News

ExCellThera announces new data to be presented at the EBMT 2022 annual meeting

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MONTRÉAL, March 15, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that new long-term data from a clinical trial using its lead technology, ECT-001, a cell therapy under clinical development, to treat patients with severe leukemia who lack a suitable donor will be presented at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). Details of the virtual presentation are as follows:

Date & Time: March 22, 2022 at 16:45 Central European Time (11:45 a.m. EDT)

Title: UM171 Expansion of Small Cord Bloods Provides Access to Safe Transplantation for Donorless Patients with Excellent Long-term Follow-up

Session: Oral Session 9: Cellular Therapies other than CARs, cell-based immune therapies, stem cell engineering

Presenter: Sandra Cohen, MD, FRCPC, Maisonneuve Rosemont Hospital, Montreal, Canada

Location: Virtual Hall 6

About ExCellThera Inc.
ExCellThera is a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in novel one-time curative therapies for patients with hematologic malignancies and other diseases. ExCellThera’s most advanced technology, ECT-001, a cell therapy, combines a proprietary molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its cell expansion and engineering platform, as well as supporting best-in-class clinical trials. excellthera.com

CONTACT: Contact:

David Desjardins
Vice President, Business and Corporate Development
david.desjardins@excellthera.com

Staff

Recent Posts

Izotropic Revises License Agreement with The Regents of the University of California

- License agreement enables U.S. FDA approval or foreign equivalent (CE mark) -- Amendment aligns…

57 minutes ago

AdvancedMD Leans Further Into Artificial Intelligence, Enhances Patient Portal Workflows and Announces New Clearinghouse Platform

As part of its 2025 Summer Product release, AdvancedMD has partnered with Waystar Clearinghouse, making…

3 hours ago

World Precision Instruments and SynVivo Announce Launch of EVOM™ Chip-A Breakthrough Multiplex TEER System Enabling Real-Time Organ-on-Chip Monitoring

SARASOTA, Fla., June 10, 2025 /PRNewswire/ -- World Precision Instruments (WPI), the global leader in transepithelial…

3 hours ago

Empowered with Meg Ryan and Youth Consultation Service Redefine Education for Diverse Learners

LOS ANGELES, June 10, 2025 /PRNewswire/ -- Public Television audiences are invited to discover a…

3 hours ago

Edison Issues Report on Electro Optic Systems (EOS)

London, United Kingdom--(Newsfile Corp. - June 10, 2025) - Edison issues report on Electro Optic…

4 hours ago